Receptor status, such as oestrogen (ER), progesterone (PR), and HER2, dictate the modern medical management of breast cancer, including neoadjuvant chemotherapy for triple-negative and ER-/HER2+ breast cancers. Here, ERBB2 is linked to breast carcinoma.